UPDATE: William Blair Initiates Coverage on Pharmacyclics on Good Market Position for Ibrutinib

In a report published Tuesday, William Blair & Company analyst Y. Katherine Xu initiated coverage on Pharmacyclics PCYC with an Outperform rating and $143.00 price target. In the report, William Blair & Company noted, “Pharmacyclics' ibrutinib is positioned to be the first of a new wave of agents ready to transform the treatment of B-cell malignancies, and we believe ibrutinib could become the largest product in hematology oncology history. We rate Pharmacyclics Outperform with a price target of $143 based on the following: 1) ibrutinib's mechanism of action allows it to address almost all B-cell malignancies, the largest patient pool among hematological malignancies; 2) ibrutinib has the best combined efficacy and safety profile among competitors and is also the first to market; 3) expanding indications as well as pushing usage from the relapsed/refractory setting to the frontline and maintenance settings will result in a gradual increase of treatment duration, which translates into increased sales potential; 4) ibrutinib's profile should allow it to become the preferred backbone for future combination regimens; and 5) there is a lack of competition within the class of BTK inhibitors.” Pharmacyclics closed on Monday at $120.76.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: Analyst ColorInitiationAnalyst RatingsWilliam Blair & CompanyY. Katherine Xu
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!